About

Click Therapeutics develops software applications that function as prescription medical treatments for patients with various health conditions. These digital therapeutics are designed to change cognitive and neurobehavioral mechanisms related to diseases, and they are tested through rigorous randomized controlled trials to ensure safety and effectiveness. After validation, the company seeks FDA clearance to market these applications as class II medical devices. Unlike traditional pharmaceuticals, Click Therapeutics' products are prescribed by physicians and reimbursed by payers, allowing for a unique revenue model. The company collaborates with established pharmaceutical firms, such as Boehringer Ingelheim, to enhance the development and commercialization of their digital therapeutics. The goal of Click Therapeutics is to provide effective, evidence-based software solutions that address unmet medical needs and improve patient outcomes.

Simplify's Take

What believers are saying

• FDA clearance of Rejoyn™ boosts credibility in digital therapeutics for mental health.
• Acquisition of Better Therapeutics expands their portfolio into cardiometabolic diseases.
• $20 million debt financing from HSBC strengthens their financial position.

What critics are saying

• Increased competition in digital therapeutics could impact market share.
• Rapid technological advancements may strain resources for software updates.
• Integration challenges from Better Therapeutics acquisition could disrupt operations.

What makes Click Therapeutics unique

• Click Therapeutics specializes in software as medical treatments for unmet medical needs.
• Their Clickometrics® platform personalizes user experience to optimize engagement and outcomes.
• Partnership with Boehringer Ingelheim highlights their strong industry collaborations.

Help us improve and share your feedback! Did you find this helpful?

YesNo